



WE CLAIM:

1. A compound having the generalized structural formula



5 wherein

 R^1 and R^2 together form a bridge containing two T^2 moieties and one T^3 moiety, said bridge, taken together with the ring to which it is attached, forming a bicyclic of structure

10 wherein

each T^2 independently represents N, CH, or CG^1 ; and
 T^3 represents S, O, CR^4G^1 , $C(R^4)_2$, or NR^3 ;

and wherein

15

 G^1 is a substituent independently selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;

20

25

- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- 5 • carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- 10 • N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- 15 • carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- 20 • -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- 25 • -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- 30 • -NO₂;
- -CN;

- amidino;
- guanidino;
- sulfo;
- $-\text{B}(\text{OH})_2$;
- 5 • optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted saturated heterocyclylalkyl;
- optionally substituted partially unsaturated heterocyclyl;
- 10 • optionally substituted partially unsaturated heterocyclylalkyl;
- $-\text{OCO}_2\text{R}^3$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- 15 • optionally substituted heteroarylalkyloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl);
- $-\text{CHO}$;
- $-\text{OCO}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$;
- 20 • $-\text{NR}^3\text{CON}(\text{R}^6)_2$

R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- 25 • H;
- alkyl;
- cycloalkyl;
- optionally substituted aryl; and
- optionally substituted aryl lower alkyl;
- 30 • lower alkyl- $\text{N}(\text{R}^3)_2$; and
- lower alkyl-OH;

R^4 is H, halogen, or lower alkyl;

p is 0, 1, or 2;

X is selected from the group consisting of O, S, and NR³;

5

Y is selected from the group consisting of

- lower alkylene;
- -CH₂-O- ;
- -CH₂-S- ;
- -CH₂-NH- ;
- -O- ;
- -S- ;
- -NH- ;
- -(CR⁴)_n-S(O)_p-(5-membered heteroaryl)-(CR⁴)_s-;
- -(CR⁴)_n-C(G²)(R⁴)-(CR⁴)_s- ;

wherein

n and s are each independently 0 or an integer of 1 – 2; and

G² is selected from the group consisting of -CN, -CO₂R³, -CON(R⁶)₂, and
-CH₂N(R⁶)₂ ;

20

- -O-CH₂- ;
- -S(O)- ;
- -S(O)₂- ;
- -SCH₂- ;
- -S(O)CH₂- ;
- -S(O)₂CH₂- ;
- -CH₂S(O)- ; and
- -CH₂S(O)₂-

Z is CR⁴ or N;

30

q is 0, 1, or 2;

G³ is a monovalent or bivalent moiety selected from the group consisting of:

- lower alkyl;
- $-\text{NR}^3\text{COR}^6$;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- 5 • $-\text{OR}^6$;
- $-\text{SR}^6$;
- $-\text{S}(\text{O})\text{R}^6$;
- $-\text{S}(\text{O})_2\text{R}^6$;
- $-\text{OCOR}^6$;
- 10 • $-\text{COR}^6$;
- $-\text{CO}_2\text{R}^6$;
- $-\text{CH}_2\text{OR}^3$;
- $-\text{CON}(\text{R}^6)_2$;
- $-\text{S}(\text{O})_2\text{N}(\text{R}^6)_2$;
- 15 • $-\text{NO}_2$;
- $-\text{CN}$;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- 20 • optionally substituted partially unsaturated heterocyclyl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- 25 • $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl);
- $-\text{OCON}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$;
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$; and
- bivalent bridge of structure $\text{T}^2=\text{T}^2-\text{T}^3$

30 wherein

 each T^2 independently represents N, CH, or CG^3 ; and

T^3 represents S, O, CR^4G^3' , $C(R^4)_2$, or NR^3 ; wherein

G^3' represents any of the above-defined moieties G^3 which are monovalent; and

the terminal T^2 is bound to L, and T^3 is bound to D, forming a 5-membered fused ring;

5

A and D independently represent N or CH;

B and E independently represent N or CH;

L represents N or CH; and

10

with the provisos that

a) the total number of N atoms in the ring containing A, B, D, E, and L is 0, 1, 2, or 3; and

b) when L represents CH and any G^3 is a monovalent substituent, at least one of A and D is an N atom; and

15

c) when L represents CH and a G^3 is a bivalent bridge of structure $T^2=T^2-T^3$, then A, B, D, and E are also CH;

J is a ring selected from the group consisting of

20

- aryl;
- pyridyl; and
- cycloalkyl;

q' represents the number of substituents G^4 on ring J and is 0, 1, 2, 3, 4, or 5, and

25

G^4 is a monovalent or bivalent moiety selected from the group consisting of


30

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;

- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- 5 • hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- phenyl lower alkoxy carbonyl-substituted alkyl;
- 10 • halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- 15 • hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- phenyl-lower alkoxy carbonyl-substituted alkylamino;
- 20 • -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- 25 • halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- 30 • -CON(R⁶)₂;
- -CH₂OR³;

- -NO_2 ;
- -CN ;
- amidino;
- guanidino;
- 5 • sulfo;
- -B(OH)_2 ;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- 10 • optionally substituted partially unsaturated heterocyclyl;
- $\text{-OCO}_2\text{R}^3$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p (optionally substituted heteroaryl);
- 15 • optionally substituted heteroarylalkyloxy;
- -S(O)_p (optionally substituted heteroarylalkyl);
- -CHO ;
- $\text{-OCON(R}^6\text{)}_2$;
- $\text{-NR}^3\text{CO}_2\text{R}^6$;
- 20 • $\text{-NR}^3\text{CON(R}^6\text{)}_2$; and
- fused ring-forming bivalent bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

a)




wherein

each T^2 independently represents N, CH, or CG^4 ;
 T^3 represents S, O, CR^4G^4 , $\text{C}(\text{R}^4)_2$, or NR^3 ; wherein

G^4 represents any of the above-defined moieties G^4 which are monovalent; and

30 binding to ring J is achieved via terminal atoms T^2 and T^3 ;

b)




wherein

each T^2 independently represents N, CH, or CG^4 ; wherein
 G^4 represents any of the above-defined moieties G^4 which are
5 monovalent; and

with the proviso that a maximum of two bridge atoms T^2 may be N ;
and

binding to ring J is achieved via terminal atoms T^2 ; and

c)



10

wherein

each T^4 , T^5 , and T^6 independently represents O, S, CR^4G^4 , $C(R^4)_2$, or
 NR^3 ; wherein

15

G^4 represents any of the above-defined moieties G^4 which are
monovalent; and

binding to ring J is achieved via terminal atoms T^4 or T^5 ;

with the provisos that:

20

- i) when one T^4 is O, S, or NR^3 , the other T^4 is CR^4G^4 or $C(R^4)_2$;
- ii) a bridge comprising T^5 and T^6 atoms may contain a maximum of
two heteroatoms O, S, or N; and
- iii) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and
one T^6 group are O atoms, or two T^6 groups are O atoms, said O
atoms are separated by at least one carbon atom;

25

when G^4 is an alkyl group located on ring J adjacent to the linkage $-(CR^4)_p-$, and X is
 NR^3 wherein R^3 is an alkyl substituent, then G^4 and the alkyl substituent R^3 on X may
be joined to form a bridge of structure $-(CH_2)_p-$ wherein p' is 2, 3, or 4, with the
proviso that the sum of p and p' is 2, 3, or 4, resulting in formation of a nitrogen-
30 containing ring of 5, 6, or 7 members;

and with the further provisos that:

- in G^1 , G^2 , G^3 , and G^4 , when two groups R^3 or R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms;

- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, $-CHO$, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCON(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, amidino, guanidino, mercapto, sulfo, and cyano; and

15


- when any alkyl group is attached to O, S, or N, and bears a hydroxyl substituent, then said hydroxyl substituent is separated by at least two carbon atoms from the O, S, or N to which the alkyl group is attached.

20

2. A compound of claim 1 wherein

R^1 and R^2

together form a bridge containing two T^2 moieties and one T^3 moiety, said bridge, taken together with the ring to which it is attached, forming a bicyclic of structure



wherein

each T^2 independently represents N, CH, or CG^1 ; and

T^3 represents S, O, CH_2 , or NR^3 ;

with the proviso that when T^3 is O or S, at least one T^2 is CH or CG^1 .

30


3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

4. A method of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to said mammal an amount of a compound of claim 1 which is effective to treat said condition.

5

5. The method of claim 4, wherein said condition is tumor growth; retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, and age-related macular degeneration; rheumatoid arthritis; psoriasis; or a bullous disorder 10 associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis.


6. A compound having the generalized structural formula



15 wherein


R¹ and R² :

- i) independently represent H or lower alkyl;
- ii) together form a bridge of structure




20 wherein binding is achieved via the terminal carbon atoms;

- iii) together form a bridge of structure



wherein binding is achieved via the terminal carbon atoms;


- iv) together form a bridge of structure



25

wherein one or two ring members T^1 are N and the others are CH or CG¹, and binding is achieved via the terminal atoms; or

v) together form a bridge containing two T^2 moieties and one T^3 moiety, said bridge, taken together with the ring to which it is attached, forming a bicyclic of structure



wherein

each T^2 independently represents N, CH, or CG¹; and
 T^3 represents S, O, CR⁴G¹, C(R⁴)₂, or NR³;

10

and wherein

m is 0 or an integer 1 – 4; and

15

G^1 is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;

20

25

30

- lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- 5 • N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- 10 • carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- 15 • -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- 20 • -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- 25 • -NO₂;
- -CN;
- amidino;
- guanidino;
- sulfo;
- 30 • -B(OH)₂;
- optionally substituted aryl;

- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted saturated heterocyclylalkyl;
- optionally substituted partially unsaturated heterocyclyl;
- 5 • optionally substituted partially unsaturated heterocyclylalkyl;
- $-\text{OCO}_2\text{R}^3$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S(O)}_p$ (optionally substituted heteroaryl);
- 10 • optionally substituted heteroarylalkyloxy;
- $-\text{S(O)}_p$ (optionally substituted heteroarylalkyl);
- $-\text{CHO}$;
- $-\text{OCON}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$;
- 15 • $-\text{NR}^3\text{CON}(\text{R}^6)_2$

R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- 20 • H;
- alkyl;
- cycloalkyl;
- optionally substituted aryl; and
- optionally substituted aryl lower alkyl;
- 25 • lower alkyl- $\text{N}(\text{R}^3)_2$; and
- lower alkyl-OH;

R^4 is H, halogen, or lower alkyl;

30 p is 0, 1, or 2;

X is selected from the group consisting of O, S, and NR^3 ;

Y is selected from the group consisting of

- lower alkylene;
- -CH₂-O- ;
- 5 • -CH₂-S- ;
- -CH₂-NH- ;
- -O- ;
- -S- ;
- -NH- ;
- 10 • -(CR⁴)_n-S(O)_p-(5-membered heteroaryl)-(CR⁴)_s- ;
- -(CR⁴)_n-C(G²)(R⁴)-(CR⁴)_s- ;

wherein

n and s are each independently 0 or an integer of 1 – 2; and

G² is selected from the group consisting of -CN, -CO₂R³, -CON(R⁶)₂, and

15 -CH₂N(R⁶)₂ ;

- -O-CH₂- ;
- -S(O)- ;
- -S(O)₂- ;
- -SCH₂- ;
- 20 • -S(O)CH₂- ;
- -S(O)₂CH₂- ;
- -CH₂S(O)- ; and
- -CH₂S(O)₂-

25 Z is N or CR⁴;

q is 1 or 2;

G³ is a monovalent or bivalent moiety selected from the group consisting of

- 30 • lower alkyl;
- -NR³COR⁶;
- carboxy-substituted alkyl;

- lower alkoxycarbonyl-substituted alkyl;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- 5 • -S(O)₂R⁶;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CH₂OR³;
- 10 • -CON(R⁶)₂;
- -S(O)₂N(R⁶)₂;
- -NO₂;
- -CN;
- optionally substituted aryl;
- 15 • optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- 20 • -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- -OCON(R⁶)₂;
- -NR³CO₂R⁶;
- 25 • -NR³CON(R⁶)₂; and
- bivalent bridge of structure T²=T²-T³:
 - wherein
 - each T² independently represents N, CH, or CG^{3'}; and
 - T³ represents S, O, CR⁴G^{3'}, C(R⁴)₂, or NR³; wherein
 - 30 G^{3'} represents any of the above-defined moieties G3 which are monovalent; and

the terminal T^2 is bound to L, and T^3 is bound to D, forming a 5-membered fused ring;

A and D are CH;

B and E are CH;

5 L is CH;

with the proviso that the resulting phenyl ring bears as a G^3 substituent said bivalent bridge of structure $T^2=T^2-T^3$;

J is a ring selected from the group consisting of

10

- aryl;
- pyridyl; and
- cycloalkyl;

q' represents the number of substituents G^4 on ring J and is 0, 1, 2, 3, 4, or 5, and

15 G^4 is a monovalent or bivalent moiety selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;

20

- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;


25

- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- phenyl lower alkoxy carbonyl-substituted alkyl;

- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- 5 • N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- 10 • phenyl-lower alkoxy carbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- 15 • halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- 20 • -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- -CN;
- 25 • amidino;
- guanidino;
- sulfo;
- -B(OH)₂;
- optionally substituted aryl;
- 30 • optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;

- optionally substituted partially unsaturated heterocyclyl;
- $-\text{OCO}_2\text{R}^3$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- 5 • $-\text{S(O)}_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S(O)}_p$ (optionally substituted heteroarylalkyl);
- $-\text{CHO}$;
- $-\text{OCON}(\text{R}^6)_2$;
- 10 • $-\text{NR}^3\text{CO}_2\text{R}^6$;
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$; and
- fused ring-forming bivalent bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

a)




15

wherein

each T^2 independently represents N, CH, or CG^4 ;
 T^3 represents S, O, CR^4G^4 , $\text{C}(\text{R}^4)_2$, or NR^3 ; wherein
 G^4 represents any of the above-defined moieties G^4 which are
20 monovalent; and
binding to ring J is achieved via terminal atoms T^2 and T^3 ;


b)



wherein

25 each T^2 independently represents N, CH, or CG^4 ; wherein
 G^4 represents any of the above-defined moieties G^4 which are
monovalent; and
with the proviso that a maximum of two bridge atoms T^2 may be N ;
and
30 binding to ring J is achieved via terminal atoms T^2 ; and

c)



wherein

each T^4 , T^5 , and T^6 independently represents O, S, CR^4G^4' , $C(R^4)_2$, or NR^3 ; wherein

5

$G4'$ represents any of the above-identified moieties $G4$ which are monovalent; and

binding to ring J is achieved via terminal atoms T^4 or T^5 ;

with the provisos that:

10

- when one T^4 is O, S, or NR^3 , the other T^4 is CR^4G^4' or $C(R^4)_2$;
- a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and
- in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom;

15

when G^4 is an alkyl group located on ring J adjacent to the linkage $-(CR^4)_p-$, and X is NR^3 wherein R^3 is an alkyl substituent, then G^4 and the alkyl substituent R^3 on X may be joined to form a bridge of structure $-(CH_2)_{p'}-$ wherein p' is 2, 3, or 4, with the proviso that the sum of p and p' is 2, 3, or 4, resulting in formation of a nitrogen-containing ring of 5, 6, or 7 members;

and with the further provisos that:

- in G^1 , G^2 , G^3 , and G^4 , when two groups R^3 or R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms;

- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy,

halogenated lower alkylthio, lower alkanoyloxy, $-\text{CO}_2\text{R}^3$, $-\text{CHO}$, $-\text{CH}_2\text{OR}^3$, $-\text{OCO}_2\text{R}^3$, $-\text{CON}(\text{R}^6)_2$, $-\text{OCON}(\text{R}^6)_2$, $-\text{NR}^3\text{CON}(\text{R}^6)_2$, nitro, amidino, guanidino, mercapto, sulfo, and cyano; and

5 - when any alkyl group is attached to O, S, or N, and bears a hydroxyl substituent, then said hydroxyl substituent is separated by at least two carbon atoms from the O, S, or N to which the alkyl group is attached.


10 7. A compound of claim 6 wherein, in the ring comprising A, B, D, E, and L and a bivalent bridge of structure $\text{T}^2=\text{T}^2-\text{T}^3$, the terminal T^2 represents N and the T^3 unit of said bridge represents S, O, CR^4_2 , or NR^3 .

15 8. A pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier.

20 9. A method of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to said mammal an amount of a compound of claim 6 which is effective to treat said condition.

25 10. The method of claim 9, wherein said condition is tumor growth; retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, and age-related macular degeneration; rheumatoid arthritis; psoriasis; or a bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis.


11. A compound having the generalized structural formula



30 wherein

R^1 and R^2 :


- independently represent H or lower alkyl;
- together form a bridge of structure



5


wherein binding is achieved via the terminal carbon atoms;

- together form a bridge of structure



wherein binding is achieved via the terminal carbon atoms;

- together form a bridge of structure




10

wherein one or two ring members T^1 are N and the others are CH or CG^1 , and binding is achieved via the terminal atoms; or

- together form a bridge containing two T^2 moieties and one T^3 moiety, said bridge, taken together with the ring to which it is attached, forming a bicyclic of structure

15



wherein

each T^2 independently represents N, CH, or CG^1 ; and
 T^3 represents S, O, CR^4G^1 , $C(R^4)_2$, or NR^3 ;

20

and wherein

m is 0 or an integer 1 – 4; and

25

G^1 is a substituent independently selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;

- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- 5 • lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- 10 • N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- 15 • phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- 20 • N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- 25 • phenyl-lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- 30 • halogenated lower alkoxy;
- halogenated lower alkylthio;

- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)₂;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- 5 optionally substituted saturated heterocyclyl;
- optionally substituted saturated heterocyclalkyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclalkyl;
- -OCO₂R³;
- 10 optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- 15 optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- 20 -CHO;
- -OCON(R⁶)₂;
- -NR³CO₂R⁶;
- 25 -NR³CON(R⁶)₂

30 R³ is H or lower alkyl;

R⁶ is independently selected from the group consisting of

- H;
- alkyl;
- cycloalkyl;
- optionally substituted aryl; and
- 5 • optionally substituted aryl lower alkyl;
- lower alkyl-N(R^3)₂; and
- lower alkyl-OH;

R^4 is H, halogen, or lower alkyl;

10

p is 0, 1, or 2;

X is selected from the group consisting of O, S, and NR³;

15 Y is selected from the group consisting of

- lower alkylene;
- -CH₂-O-;
- -CH₂-S-;
- -CH₂-NH-;
- 20 • -O-;
- -S-;
- -NH-;
- -(CR⁴)_n-S(O)_p-(5-membered heteroaryl)-(CR⁴)_s-;
- -(CR⁴)_n-C(G²)(R⁴)-(CR⁴)_s-;

25 wherein

n and s are each independently 0 or an integer of 1 – 2; and

G² is selected from the group consisting of -CN, -CO₂R³, -CON(R⁶)₂, and
-CH₂N(R⁶)₂;

- -O-CH₂-;
- 30 • -S(O)-;
- -S(O)₂-;
- -SCH₂-;

- $-\text{S}(\text{O})\text{CH}_2-$;
- $-\text{S}(\text{O})_2\text{CH}_2-$;
- $-\text{CH}_2\text{S}(\text{O})-$; and
- $-\text{CH}_2\text{S}(\text{O})_2-$

5

Z is CR^4 ;

q is 1 or 2;

10 G^3 is a monovalent or bivalent moiety selected from the group consisting of

- $-\text{NR}^3\text{COR}^6$;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- $-\text{OR}^6$;

15

- $-\text{SR}^6$;
- $-\text{S}(\text{O})\text{R}^6$;
- $-\text{S}(\text{O})_2\text{R}^6$;
- $-\text{OCOR}^6$;
- $-\text{COR}^6$;

20

- $-\text{CO}_2\text{R}^6$;
- $-\text{CH}_2\text{OR}^3$;
- $-\text{CON}(\text{R}^6)_2$;
- $-\text{S}(\text{O})_2\text{N}(\text{R}^6)_2$;
- $-\text{NO}_2$;

25

- $-\text{CN}$;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;

30

- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);

- optionally substituted heteroarylalkyloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl);
- $-\text{OCON}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$;
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$; and
- bivalent bridge of structure $\text{T}^2=\text{T}^2-\text{T}^3$
 - wherein
 - each T^2 independently represents N, CH, or CG^3 ; and
 - T^3 represents S, O, CR^4G^3 , $\text{C}(\text{R}^4)_2$, or NR^3 ; wherein
 - G^3 represents any of the above-defined moieties G³ which are monovalent; and
 - the terminal T^2 is bound to L, and T^3 is bound to D, forming a 5-membered fused ring;

15 A and D independently represent N or CH;
 B and E independently represent N or CH;
 L represents N or CH;
 with the provisos that

- a) the total number of N atoms in the ring containing A, B, D, E, and L is 0, 1, 2, or 3; and
- b) when L represents CH and any G³ is a monovalent substituent, at least one of A and D is an N atom; and
- c) when L represents CH and a G³ is a bivalent bridge of structure $\text{T}^2=\text{T}^2-\text{T}^3$, then A, B, D, and E are also CH;

25 J is a ring selected from the group consisting of

- aryl;
- pyridyl; and
- cycloalkyl;

30 q' represents the number of substituents G⁴ on ring J and is 0, 1, 2, 3, 4, or 5, and G⁴ is a monovalent or bivalent moiety selected from the group consisting of

- $-\text{N}(\text{R}^6)_2$;
- $-\text{NR}^3\text{COR}^6$;
- halogen;
- alkyl;
- 5 • cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- 10 • N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- 15 • carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- 20 • N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- 25 • carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- $-\text{OR}^6$;
- $-\text{SR}^6$;
- 30 • $-\text{S}(\text{O})\text{R}^6$;
- $-\text{S}(\text{O})_2\text{R}^6$;

- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;

5 • -COR⁶;

- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;

10 • -CN;

- amidino;
- guanidino;
- sulfo;
- -B(OH)₂;

15 • optionally substituted aryl;

- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- -OCO₂R³;


20 • optionally substituted heteroarylalkyl;

- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);

25 • -CHO;

- -OCON(R⁶)₂;
- -NR³CO₂R⁶;
- -NR³CON(R⁶)₂; and
- fused ring-forming bivalent bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

30 a)



wherein


each T^2 independently represents N, CH, or CG^4 ;

T^3 represents S, O, CR^4G^4' , $C(R^4)_2$, or NR^3 ; wherein

5 $G4'$ represents any of the above-defined moieties $G4$ which are monovalent; and

binding to ring J is achieved via terminal atoms T^2 and T^3 ;

b)



10 wherein


each T^2 independently represents N, CH, or CG^4 ; wherein

$G4'$ represents any of the above-defined moieties $G4$ which are monovalent; and

15 with the proviso that a maximum of two bridge atoms T^2 may be N ; and

binding to ring J is achieved via terminal atoms T^2 ; and

c)



wherein

20 each T^4 , T^5 , and T^6 independently represents O, S, CR^4G^4' , $C(R^4)_2$, or NR^3 ; wherein

$G4'$ represents any of the above-defined moieties $G4$ which are monovalent; and

binding to ring J is achieved via terminal atoms T^4 or T^5 ;

25 with the provisos that:

- when one T^4 is O, S, or NR^3 , the other T^4 is CR^4G^4' or $C(R^4)_2$;
- a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and

iii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;

5 when G⁴ is an alkyl group located on ring J adjacent to the linkage -(CR⁴)_p- , and X is NR³ wherein R³ is an alkyl substituent, then G⁴ and the alkyl substituent R³ on X may be joined to form a bridge of structure -(CH₂)_{p'} - wherein p' is 2, 3, or 4, with the proviso that the sum of p and p' is 2, 3, or 4, resulting in formation of a nitrogen-containing ring of 5, 6, or 7 members;

10

and with the further provisos that:

- in G¹, G², G³, and G⁴, when two groups R³ or R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a N-containing heterocycle of 5 – 7 ring atoms;

15

- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, -CO₂R³, -CHO, -CH₂OR³, -OCO₂R³, -CON(R⁶)₂, -OCON(R⁶)₂, -NR³CON(R⁶)₂, nitro, amidino, guanidino, mercapto, sulfo, and cyano; and

20

- when any alkyl group is attached to O, S, or N, and bears a hydroxyl substituent, then said hydroxyl substituent is separated by at least two carbon atoms from the O, S, or N to which the alkyl group is attached.

25 12. A compound of claim 11 wherein R⁴ is H.

30

13. A pharmaceutical composition comprising a compound of claim 11 and a pharmaceutically acceptable carrier.

14. A method of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to said mammal an amount of a compound of claim 11 which is effective to treat said condition.

5

15. The method of claim 14, wherein said condition is tumor growth; retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, and age-related macular degeneration; rheumatoid arthritis; psoriasis; or a bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis.

10

16. A compound selected from the group consisting of examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 27, 28, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 15 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 78, 79, 82A, 82B, 82C, 82D, 85, 88, 89, 93, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, and 112.